Abstract
Breast cancer progression is shaped by the interaction of oncogenic signaling with chronic inflammation. Two pathways implicated in this process are NLRP3 inflammasome activation, which drives maturation of IL-1β and IL-18 and thereby reshapes the tumor microenvironment, and canonical Wnt/β-catenin signaling, which promotes proliferation, epithelial–mesenchymal transition, and stem-like properties. In this narrative review, we examine the evidence that microRNAs (miRNAs) may couple these pathways, and grade that evidence by directness and biological context. Oncogenic miRNAs including miR-21, miR-155, miR-301a, and miR-374a have been reported to enhance β-catenin signaling through suppression of PTEN and WIF1 while concurrently promoting inflammasome priming via NF-κB, whereas miR-223-3p, miR-296-5p, and miR-590-5p have been described as attenuating both. For most, however, direct experimental validation exists for only one arm of the proposed circuit, and no study has demonstrated coordinate regulation of both pathways by a single miRNA within the same breast cancer cellular context at physiological expression levels. The mechanistic anchor of the proposed module, the association of β-catenin with NLRP3 that enhances NLRP3–ASC assembly, was characterised in macrophage systems and not in breast tumour cells. We therefore distinguish evidence obtained in triple-negative breast cancer from that extrapolated from other malignancies and non-cancer inflammatory models, and note the context-dependent effects of NLRP3 signaling and pyroptosis. Therapeutic and biomarker strategies are discussed as hypotheses: no agent targeting this axis has been evaluated clinically in breast cancer. Validation in defined tumour and immune compartments, patient-derived models, and clinical cohorts is required before firm conclusions can be drawn.
Keywords: breast cancer, inflammation, microRNA, NLRP3 inflammasome, Wnt/β-catenin signaling
Graphical Abstract

1. Introduction
Breast cancer remains the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. According to the World Health Organization, approximately 2.3 million new cases and 685, 000 deaths were reported globally in 2020 (1). Despite significant advances in early detection, molecular diagnostics, and targeted therapeutic strategies, a substantial proportion of patients progress to aggressive, metastatic, or therapy-resistant disease states (2, 3). Increasing evidence suggests that breast cancer progression is not solely driven by genetic alterations and uncontrolled cellular proliferation, but is also critically influenced by chronic inflammation and complex interactions between oncogenic signaling pathways and the tumor microenvironment (4–6). Among the key regulatory axes implicated in this interplay are the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome and the Wnt/β-catenin signaling pathway. These systems represent distinct yet interconnected mechanisms that collectively modulate tumor growth, immune evasion, and therapeutic resistance (7, 8). The NLRP3 inflammasome is a cytosolic multiprotein complex of the innate immune system, comprising the sensor molecule NLRP3, the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and the effector pro-caspase-1 (9, 10). Direct evidence of canonical NLRP3 inflammasome activation in breast cancer tissues remains limited; elevated levels of IL-1β and its receptor signaling axis strongly implicate inflammasome-driven inflammatory processes in tumor progression (11).
In parallel, the Wnt/β-catenin signaling pathway plays a central role in regulating cell fate determination, proliferation, differentiation, and the maintenance of cancer stem-like properties (12). In the absence of Wnt ligands, β-catenin is targeted for proteasomal degradation by a destruction complex composed of APC, Axin, and GSK-3β. Activation of the pathway through Wnt ligand binding to Frizzled (FZD) receptors and LRP5/6 co-receptors disrupts this complex, resulting in β-catenin stabilization, cytoplasmic accumulation, and subsequent nuclear translocation. Nuclear β-catenin associates with TCF/LEF transcription factors to drive the expression of oncogenic target genes, including Cyclin D1, c-Myc, and matrix metalloproteinases (MMPs). Aberrant activation of Wnt signaling has been extensively linked to epithelial–mesenchymal transition (EMT), cancer stemness, chemoresistance, and metastatic progression in breast cancer (13). Emerging studies have revealed a functional and bidirectional crosstalk between Wnt/β-catenin signaling and the NLRP3 inflammasome (14, 15). Mechanistically, β-catenin has been shown to directly interact with NLRP3, facilitating inflammasome assembly and enhancing caspase-1 activation, thereby promoting IL-1β secretion. Conversely, IL-1β signaling activates NF-κB, a transcription factor that induces the expression of Wnt ligands and amplifies β-catenin–dependent transcriptional programs (16). This positive feedback loop establishes a sustained pro-tumorigenic state characterized by concurrent activation of inflammatory and oncogenic signaling pathways, which may ultimately contribute to increased tumor aggressiveness and therapeutic resistance.
MicroRNAs (miRNAs), a class of small non-coding RNAs typically 18–22 nucleotides in length, have emerged as critical post-transcriptional regulators that integrate these signaling networks (17, 18). Accumulating evidence highlights the role of specific miRNAs in simultaneously modulating both Wnt/β-catenin signaling and NLRP3 inflammasome activation in breast cancer. Oncogenic miRNAs, such as miR-21 and miR-155, are frequently upregulated in breast tumors and enhance β-catenin signaling by targeting negative regulators including PTEN, APC, and GSK-3β (19). Concurrently, these miRNAs promote inflammasome activation through NF-κB–mediated priming or by suppressing endogenous inhibitors of NLRP3, such as BRCC3. In contrast, tumor-suppressive miRNAs, including miR-223-3p, miR-296-5p, and miR-590-5p, function as critical modulators that attenuate both oncogenic signaling and inflammatory responses (20). Notably, miR-223-3p directly targets NLRP3 mRNA, reducing IL-1β production, while miR-296-5p and miR-590-5p inhibit Wnt pathway components such as FGFR1 and PITX2, thereby exerting anti-tumorigenic and anti-inflammatory effects (21).
These findings position miRNAs as key molecular nodes that coordinate the interplay between oncogenic signaling and inflammasome-driven inflammation. Their dual regulatory capacity highlights their potential as both diagnostic biomarkers and therapeutic targets in breast cancer. Several reviews have independently addressed Wnt/β-catenin signaling in breast cancer, the role of the NLRP3 inflammasome in tumour-associated inflammation, and miRNA-mediated regulation of inflammasome components, the latter largely confined to triple-negative disease. These have, however, treated the two pathways as parallel rather than coupled axes, and miRNAs have typically been catalogued as regulators of one pathway or the other. To our knowledge, no previous review has systematically assembled the evidence that a discrete subset of miRNAs acts simultaneously on both arms of a β-catenin–NLRP3 feedback circuit across breast cancer subtypes. The present review differs in three respects. First, it uses the physical interaction between β-catenin and NLRP3, which enhances NLRP3–ASC association and caspase-1 activation, as the mechanistic anchor that converts two separate pathways into a single integrated module; we note that this interaction has been demonstrated in non-breast systems and indicate throughout where evidence is extrapolated from other tumour types or inflammatory models. Second, it re-classifies the relevant miRNAs not by tissue of origin or expression direction alone, but by their position within this module as amplifiers, dampeners, or feedback-locked components, compiled in a single target-resolved framework. Third, it translates this framework into testable predictions for combinatorial therapy and for composite miRNA–cytokine biomarker signatures, rather than reiterating single-agent Wnt or NLRP3 inhibition.
1.1. Review methodology
This narrative review was based on a structured search of PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for English-language, peer-reviewed articles published up to July 2026, combining the terms “breast cancer”, “triple-negative breast cancer”, “TNBC”, “microRNA”, “miRNA”, “Wnt”, “β-catenin”, “NLRP3”, “inflammasome”, “pyroptosis”, and “tumor microenvironment” with the names of individual miRNAs discussed here. Primary experimental studies were prioritised for mechanistic claims; reviews were used for background and to identify additional primary sources. Evidence was categorised by biological context as TNBC-specific, general breast cancer, other malignancies, or non-cancer inflammatory and immune models, with the latter two regarded as mechanistically informative but extrapolative. A miRNA–target interaction was classified as direct when supported by experimental target validation, particularly 3′-UTR reporter assays together with expression, loss- or gain-of-function, or rescue experiments, and as indirect when regulation occurred through an intermediate molecular regulator; associations lacking sufficient mechanistic validation were designated limited or proposed. A miRNA was not considered a confirmed regulator of both Wnt/β-catenin and NLRP3 signaling solely on the basis of independent studies linking it separately to each pathway.
2. Role of NLRP3 inflammasomes
The NLRP3 inflammasome is a critical cytosolic multiprotein complex of the innate immune system, composed of the NLRP3 sensor scaffold, the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), and the effector enzyme pro-caspase-1 (22). It functions as a key molecular sensor of cellular stress and damage signals (9). Upon activation by diverse stimuli-including extracellular ATP, reactive oxygen species (ROS), and priming signals mediated through NF-κB-NLRP3 undergoes oligomerization and recruits ASC and pro-caspase-1 to form an inflammasome complex. This assembly facilitates the autocatalytic cleavage of pro-caspase-1 into its active form, which subsequently processes pro-inflammatory cytokines, leading to the maturation and secretion of interleukin-1β (IL-1β) and interleukin-18 (IL-18), as well as the induction of pyroptotic cell death (23).
In the context of cancer, the role of NLRP3 inflammasome signaling is highly context-dependent, exhibiting both tumor-suppressive and tumor-promoting functions. However, in breast cancer, accumulating evidence predominantly supports a pro-tumorigenic role. Activation of the NLRP3 inflammasome in tumor-associated macrophages and malignant epithelial cells leads to increased secretion of IL-1β and IL-18, thereby promoting a pro-inflammatory tumor microenvironment. This inflammatory milieu facilitates key processes associated with tumor progression, including angiogenesis, epithelial–mesenchymal transition (EMT), and immune evasion. Notably, elevated expression levels of NLRP3 and IL-1β have been correlated with aggressive breast cancer phenotypes, underscoring their potential clinical relevance (24).
Mechanistically, metabolic and hormonal factors further modulate inflammasome activation. For instance, the adipokine leptin has been shown to activate NLRP3 signaling through estrogen receptor–dependent pathways, thereby providing a mechanistic link between obesity and inflammasome-driven breast cancer progression. Importantly, both genetic ablation and pharmacological inhibition of NLRP3 have been demonstrated to suppress tumor growth and metastatic dissemination in preclinical breast cancer models, highlighting its functional significance (25).
At the microenvironmental level, NLRP3 activation contributes to the establishment of an immunosuppressive niche by promoting the recruitment of myeloid-derived suppressor cells (MDSCs) and attenuating anti-tumor immune responses. This immunomodulatory effect is particularly relevant in aggressive subtypes such as triple-negative breast cancer (TNBC), where sustained inflammasome activation has been implicated in the maintenance of cancer stem-like properties and the development of chemoresistance. Collectively, these findings position the NLRP3 inflammasome as both a biomarker and a key driver of tumor progression in breast cancer, as well as a potential therapeutic target for intervention (26).
2.1. NLRP3 structure
The identification of pattern recognition receptors (PRRs) and their associated signaling pathways represents a major advance in our understanding of innate immunity. PRRs constitute a diverse group of germline-encoded receptors that detect conserved molecular signatures derived from pathogens, termed pathogen-associated molecular patterns (PAMPs), as well as endogenous danger-associated molecular patterns (DAMPs) released during cellular stress or tissue damage. Among the principal families of PRRs are Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs), each of which contributes to the initiation of host immune responses (27, 28).
The NLR family comprises a large group of cytosolic sensors, including 22 identified members in humans and at least 34 in murine systems. NLRP3 is one of the most extensively studied members due to its pivotal role in inflammasome assembly and inflammatory signaling. Structurally, NLRP3 is a tripartite protein consisting of an N-terminal pyrin domain (PYD), a central nucleotide-binding and oligomerization domain (NACHT), and a C-terminal leucine-rich repeat (LRR) domain (29). The NACHT domain mediates ATP-dependent oligomerization, a critical step for inflammasome assembly, whereas the LRR domain is involved in ligand sensing and autoregulation. The N-terminal PYD facilitates homotypic interactions with the adaptor protein ASC, enabling the recruitment of downstream signaling components (28). Given its central role in inflammation, the NLRP3 inflammasome has emerged as an attractive therapeutic target. Multiple pharmacological strategies have been developed to inhibit different stages of inflammasome activation. These include direct inhibition of NLRP3 activation (e.g., MCC950), inhibition of caspase-1 activity (e.g., VX-765), and blockade of downstream cytokine signaling through IL-1 receptor antagonists (e.g., Anakinra) or neutralizing antibodies targeting IL-1β (e.g., Canakinumab) and IL-18 (e.g., IL-18BP). These targeted approaches highlight the therapeutic potential of modulating inflammasome signaling in inflammatory diseases and cancer (30).
2.2. Activation of NLRP3 inflammasome
Under basal conditions, NLRP3 remains in an inactive, autorepressed state, and its activation requires a tightly regulated two-step process involving priming and activation (31). The priming step is initiated through the engagement of pattern recognition receptors, including Toll-like receptors (TLRs), and cytokine receptors such as tumor necrosis factor receptor (TNFR) and interleukin-1 receptor (IL-1R). Recognition of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) activates NF-κB signaling, leading to transcriptional upregulation of NLRP3 and pro-IL1B (32). This licensing step is essential to establish a competent inflammasome response. In certain cell types, particularly human monocytes, priming alone has been reported to be sufficient to induce caspase-1 activation and IL-1β release, highlighting cell type–specific differences in inflammasome regulation. Notably, IL-1 signaling itself has been implicated in promoting both primary tumor growth and metastatic progression in breast cancer (33).
The second step involves activation of the inflammasome in response to a wide array of stimuli that disrupt cellular homeostasis. These include extracellular ATP, uric acid crystals, cholesterol crystals, calcium phosphate crystals, reactive oxygen species (ROS), and metabolic stress signals. A well-characterized mechanism involves lipopolysaccharide (LPS)-induced release of endogenous ATP, which activates purinergic P2X7 receptors, resulting in potassium efflux and subsequent NLRP3 activation (34). In addition to this canonical pathway, alternative signaling mechanisms have been described. For instance, in human monocytes, TLR4 signaling through the TRIF adaptor recruits receptor-interacting serine/threonine protein kinase 1 (RIPK1), Fas-associated death domain protein (FADD), and caspase-8, thereby enabling inflammasome activation independently of classical ion flux pathways. Although the fundamental mechanisms are conserved, species-specific differences between human and murine systems remain incompletely understood (27, 35, 36).
Beyond canonical activation, non-canonical and virus-induced pathways further expand the functional landscape of NLRP3 signaling. In murine systems, caspase-11-and its human homologs caspase-4 and caspase-5-can directly sense intracellular lipopolysaccharide, triggering gasdermin D–mediated pore formation and secondary activation of the NLRP3 inflammasome. During influenza A virus infection, Z-DNA-binding protein 1 (ZBP1) detects viral Z-RNA and promotes the formation of a ZBP1–NLRP3 inflammasome complex through recruitment of RIPK3 and caspase-8, thereby linking viral sensing to inflammasome activation and pyroptotic cell death (37).
The activation of the NLRP3 inflammasome is further modulated by a network of positive and negative regulatory factors. Positive regulators include adaptor proteins such as MyD88 and TRIF, as well as signaling intermediates like caspase-8, FADD, and the RNA helicase DDX3X (38), which directly interacts with NLRP3 to facilitate its activation. Additionally, host factors such as SHARPIN, interferon signaling components, and immunity-related GTPases contribute to fine-tuning inflammasome assembly and function (3, 37, 38).
Conversely, several negative regulators act to restrain excessive inflammasome activation and maintain cellular homeostasis. The E3 ubiquitin ligase A20 (TNFAIP3) suppresses NLRP3 activation by limiting NF-κB signaling and inflammasome assembly (39). Tumor suppressor pathways also intersect with inflammasome regulation; for instance, p53 has been implicated in modulating inflammatory responses under conditions of cellular stress. Furthermore, resveratrol has been shown to inhibit NLRP3 activation through a SIRT1–p53–dependent pathway, linking metabolic regulation and cellular aging to inflammasome control. Transforming growth factor-β–activated kinase 1 (TAK1) also functions as a critical negative regulator, preventing spontaneous inflammasome activation and preserving immune homeostasis (40). These multilayered regulatory mechanisms underscore the complexity of NLRP3 inflammasome activation and highlight its central role as a sensor and amplifier of inflammatory signaling in both physiological and pathological contexts.
3. Wnt/β-catenin signaling in breast cancer
Aberrant activation of the Wnt/β-catenin signaling pathway is a well-established feature of breast cancer (BC), although activating mutations in CTNNB1 (encoding β-catenin) are relatively uncommon. Instead, dysregulation of this pathway in BC is predominantly driven by alterations in upstream regulators, ligand availability, and pathway modulators (41). Notably, β-catenin expression and localization exhibit marked heterogeneity across breast cancer subtypes. Elevated β-catenin levels are frequently observed in invasive ductal carcinoma (IDC), with reported expression rates of approximately 70–75%, whereas invasive lobular carcinoma (ILC) demonstrates significantly lower expression, typically ranging from 10–14%. These differences suggest subtype-specific roles of Wnt signaling in tumor biology (42).
Proteomic analyses have further provided insight into the downstream consequences of Wnt/β-catenin activation. In particular, comparative nucleolar proteomic studies in triple-negative breast cancer (TNBC) cells have identified a subset of nucleolar proteins as potential β-catenin–regulated effectors. These proteins are implicated in ribosomal biogenesis, cellular stress responses, and proliferative signaling, thereby contributing to the aggressive phenotype and poor clinical prognosis associated with TNBC (43).
In contrast to other breast cancer subtypes, activation of Wnt/β-catenin signaling in metaplastic breast cancer-a rare but highly aggressive form often classified within the TNBC spectrum-is more directly associated with genetic alterations. Mutations in key pathway components, including CTNNB1 and APC, have been reported to drive constitutive β-catenin activation in this subtype. Importantly, tumor suppressor molecules such as cellular communication network factor 6 (CCN6) act as negative regulators of Wnt signaling. CCN6 has been shown to interact with Frizzled-8 (FZD8) and LRP6 co-receptors, thereby inhibiting Wnt-induced β-catenin/TCF transcriptional activity. Loss or downregulation of CCN6 disrupts this regulatory axis, facilitating enhanced Wnt signaling and contributing to tumor progression (44, 45) (Figure 1).
Figure 1.

Overview of canonical and non-canonical Wnt signaling pathways in cancer. Canonical Wnt/β-catenin signaling stabilizes β-catenin, enabling nuclear translocation and TCF/LEF-mediated transcription of genes involved in proliferation, survival, and metastasis. Non-canonical Wnt signaling activates PCP and Wnt/Ca²+ pathways, regulating cytoskeletal remodeling, migration, calcium homeostasis, cell adhesion, and metastatic progression.
4. The role of NLRP3 in breast cancer
Breast cancer represents the most frequently diagnosed malignancy among women and remains a leading contributor to cancer-related mortality worldwide (46). Increasing evidence highlights the contribution of innate immune signaling pathways, particularly inflammasomes, in shaping tumor progression. Inflammasomes are multiprotein signaling complexes that are activated in response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), leading to the maturation and secretion of pro-inflammatory cytokines. Among these, the NLRP3 inflammasome has emerged as a critical regulator of tumor-associated inflammation in breast cancer. Accumulating studies indicate that aberrant activation of the NLRP3 inflammasome contributes to multiple hallmarks of breast cancer progression. Activation of NLRP3 promotes caspase-1–dependent processing of IL-1β and IL-18, thereby establishing a pro-inflammatory tumor microenvironment that facilitates tumor cell proliferation, angiogenesis, invasion, and metastatic dissemination (24). Elevated local levels of IL-1β have been consistently associated with breast tumor development in preclinical models, underscoring its functional relevance. Furthermore, caspase-1 activation has been linked to increased expression of matrix metalloproteinase-9 (MMP-9), a key mediator of extracellular matrix remodeling that contributes to tumor invasion, metastasis, and radioresistance (47).
In addition to its direct effects on tumor cells, NLRP3 signaling exerts profound immunomodulatory functions within the tumor microenvironment. Activation of the inflammasome has been shown to suppress anti-tumor immune responses by impairing the activity of cytotoxic T lymphocytes and natural killer (NK) cells (48). This immunosuppressive milieu is reinforced through activation of key inflammatory signaling pathways, including NF-κB, STAT1/3, and the IL-1β/IL-1 receptor axis, which further intersects with β-catenin–mediated oncogenic signaling. Collectively, these pathways establish a feed-forward loop that sustains tumor-promoting inflammation and enhances disease progression.
Metabolic and hormonal factors further modulate NLRP3 activity in breast cancer (25). Notably, the adipokine leptin has been shown to promote breast cancer cell migration and proliferation by activating the NLRP3 inflammasome and enhancing IL-18 production, thereby linking obesity-associated metabolic dysregulation with tumor progression. In contrast, adiponectin, particularly its globular form, exhibits anti-tumorigenic properties by inhibiting NLRP3 inflammasome activation and suppressing breast cancer cell growth (49). Additionally, genetic factors such as deficiency of the breast cancer susceptibility gene BRCA1 have been associated with dysregulated mitochondrial function and enhanced NLRP3 inflammasome activation, further implicating inflammasome signaling in tumor biology (50).
4.1. The role of NLRP3 in TNBC
Triple-negative breast cancer (TNBC) represents one of the most aggressive subtypes of breast cancer, characterized by a high proliferative index, early recurrence, and limited therapeutic options due to the absence of hormone receptors and HER2 expression. Increasing evidence implicates dysregulated inflammatory signaling, particularly inflammasome activation, in the progression and therapeutic resistance of TNBC (5).
Upon assembly, ASC forms characteristic speck-like structures that recruit pro-caspase-1, facilitating its cleavage into active caspase-1. Activated caspase-1 processes pro-inflammatory cytokines, including IL-1β and IL-18, into their mature forms and induces pyroptosis through cleavage of gasdermin D (GSDMD). The resulting N-terminal fragments of GSDMD form membrane pores (approximately 10–20 nm in diameter), leading to ionic flux, cellular swelling, membrane rupture, and release of inflammatory mediators (51). Pyroptosis represents a highly inflammatory form of programmed cell death, with dual roles in cancer biology. While it can promote anti-tumor immunity by enhancing immunogenic cell death, persistent or dysregulated pyroptosis may contribute to tumor progression by sustaining a chronic inflammatory tumor microenvironment (15).
In TNBC, aberrant activation of the NLRP3 inflammasome has been strongly associated with tumor aggressiveness. Elevated expression of NLRP3, caspase-1, IL-1β, and IL-18 has been observed in aggressive tumor phenotypes and is linked to activation of inflammatory signaling pathways, including NF-κB. The TNBC tumor microenvironment is characterized by elevated levels of reactive oxygen species (ROS), reactive nitrogen species (RNS), cytokines, chemokines, and pro-angiogenic factors, all of which contribute to inflammasome activation and sustain tumor-promoting inflammation (52). This inflammatory milieu enhances tumor cell proliferation, invasion, angiogenesis, and metastatic potential (53).
The classification of inflammasomes further highlights their complexity. Canonical inflammasomes include members of the NLR family such as NLRP1, NLRP3, NLRP6, and NLRC4, whereas non-canonical inflammasomes involve caspase-4 and caspase-5 in humans (and caspase-11 in mice), which can directly sense intracellular lipopolysaccharide and activate downstream inflammatory responses (54). Additionally, AIM2-like receptors (e.g., AIM2 and IFI16) and pyrin-based inflammasomes contribute to inflammasome diversity. Although the molecular mechanisms underlying non-canonical inflammasome signaling remain incompletely defined, their role in inflammation and cancer progression is increasingly recognized (55). From a therapeutic perspective, targeting inflammasome signaling represents a promising strategy in TNBC.
4.2. The role of NLRP3 in breast tumor microenvironment
The tumor microenvironment (TME) plays a critical role in breast cancer progression by integrating inflammatory, stromal, and immune signaling networks. Activation of the NLRP3 inflammasome has emerged as a key contributor to this dynamic microenvironment, promoting epithelial–mesenchymal transition (EMT), angiogenesis, metastatic dissemination, and resistance to apoptosis. In addition, inflammasome signaling is closely linked to immune modulation and pyroptosis, an inflammatory form of programmed cell death that can exert both tumor-promoting and tumor-suppressive effects depending on the context (56).
Inflammatory cell infiltration within the breast TME is increasingly recognized as an important prognostic indicator. The TME is composed of diverse cellular populations, including tumor-infiltrating lymphocytes, tumor-associated macrophages (TAMs), fibroblasts, and myeloid-derived suppressor cells (MDSCs), which collectively secrete a wide array of cytokines, chemokines, growth factors, and proteolytic enzymes (57). These factors contribute to tumor progression by enhancing cellular proliferation, promoting angiogenesis, and facilitating immune evasion. Notably, pro-inflammatory cytokines such as IL-1, IL-6, IL-8, IL-11, IL-18, and IL-23 are frequently upregulated in the breast tumor stroma and are strongly associated with invasive and metastatic phenotypes, particularly in triple-negative breast cancer (TNBC) (53).
Within this context, activation of the NLRP3 inflammasome serves as a central driver of inflammatory signaling. Elevated NLRP3 activity has been associated with increased tumor cell proliferation and invasion, as well as the establishment of a pro-tumorigenic inflammatory niche (58). Mechanistically, NLRP3 activation promotes the recruitment and expansion of immunosuppressive cell populations, including MDSCs and TAMs, thereby attenuating anti-tumor immune responses. Furthermore, NLRP3 signaling has been implicated in tumor lymphangiogenesis and the promotion of distant metastasis, particularly to the lungs, highlighting its role in systemic disease progression (59).
Recent advances in understanding TME-associated signaling pathways have opened new avenues for therapeutic intervention. Conventional treatment strategies for breast cancer, including anthracycline- and taxane-based chemotherapy, remain the standard of care in neoadjuvant and adjuvant settings. Additional modalities such as surgery (mastectomy or lumpectomy), radiotherapy, and targeted agents-including paclitaxel, doxorubicin, cisplatin, carboplatin, and bevacizumab-are widely used. However, despite these approaches, TNBC remains highly heterogeneous and is frequently associated with chemoresistance, high relapse rates, and significant treatment-related toxicities, including myelosuppression, neuropathy, and systemic adverse effects (60). The limitations of conventional therapies have prompted the development of advanced therapeutic strategies aimed at improving drug delivery and targeting tumor-specific pathways. Nanoparticle-based systems exploiting the enhanced permeability and retention (EPR) effect have been employed for passive targeting (61, 62), while active targeting approaches-including microRNA-based therapeutics and aptamer-guided delivery systems-offer improved specificity and therapeutic efficacy. These strategies hold promise for modulating key signaling pathways within the TME, including inflammasome-associated networks.
Importantly, inflammasome signaling is closely linked to the establishment of an immunosuppressive TME in breast cancer. Activation of innate immune pathways, including Toll-like receptor (TLR) signaling, facilitates the recognition of DAMPs and initiates downstream cascades that promote ASC recruitment, inflammasome assembly, and cytokine release (63). This sustained inflammatory signaling contributes to immune dysfunction and tumor progression. Additionally, emerging evidence suggests that overexpression of gasdermin family members, such as gasdermin B (GSDMB), may influence therapeutic response, with elevated GSDMB levels being associated with reduced efficacy of HER2-targeted therapies (64) (Figure 2).
Figure 2.

Schematic illustration of NLRP3 inflammasome activation in breast cancer. PAMPs, DAMPs, and ATP trigger NF-κB-mediated priming and NLRP3 inflammasome assembly with ASC and caspase-1. Activated caspase-1 cleaves pro-IL-1β, pro-IL-18, and GSDMD, inducing pyroptosis and cytokine release, thereby promoting angiogenesis, epithelial–mesenchymal transition, tumor proliferation, and immunosuppressive microenvironments.
5. non-coding RNAs in NLRP3 inflammasome and breast cancer
Advances in high-throughput sequencing technologies have led to the identification of a diverse class of non-coding RNAs (ncRNAs) transcribed from non-protein-coding regions of the genome. These molecules have emerged as critical regulators of gene expression, influencing cellular processes such as proliferation, differentiation, apoptosis, and tissue homeostasis. Increasing evidence implicates ncRNAs in the pathogenesis of a wide range of human diseases, including cancer, autoimmune disorders, metabolic dysfunction, and chronic inflammatory conditions (65).
In the context of cancer, dysregulation of ncRNAs can occur through genetic and epigenetic alterations, including mutations in promoter regions and aberrant activity of key enzymes involved in ncRNA biogenesis, such as DROSHA and DICER (66). Such alterations disrupt normal gene regulatory networks and contribute to tumor initiation, progression, and metastasis. Notably, altered expression profiles of ncRNAs have been consistently associated with aggressive disease phenotypes and poor clinical outcomes in breast cancer (67).
Among ncRNAs, microRNAs (miRNAs) represent one of the most extensively studied subclasses, functioning as post-transcriptional regulators that fine-tune gene expression. A growing body of evidence highlights the involvement of specific oncogenic miRNAs (oncomiRs) in modulating both breast cancer progression and inflammasome signaling pathways. For instance, miR-373 has been identified as a metastasis-promoting miRNA in breast cancer, enhancing tumor cell proliferation, migration, and invasion, in part through targeting CD44. In addition, miR-373 has been implicated in the regulation of caspase-8–mediated non-canonical inflammasome activation, thereby linking tumor progression with inflammatory signaling (68).
Similarly, miR-135b has been shown to promote breast cancer cell proliferation and invasion, while concurrently modulating inflammatory responses by influencing caspase-1 expression. miR-210, a hypoxia-responsive miRNA, plays a multifaceted role in breast cancer by regulating cellular adaptation to hypoxic stress, apoptosis, and metastatic potential. In triple-negative breast cancer (TNBC), miR-301b is frequently upregulated and contributes to tumor growth, migration, invasion, and endocrine resistance through activation of the TLR4/NF-κB signaling axis, which is closely associated with inflammasome priming (69, 70).
Additional miRNAs further underscore the complexity of ncRNA-mediated regulation of inflammasome signaling. miR-663a has been reported to promote apoptotic responses through modulation of pro-inflammatory cytokine maturation and is often dysregulated in TNBC. miR-638 has been implicated in metabolic reprogramming by regulating ATP synthesis pathways, thereby contributing to tumor progression and potentially influencing inflammasome assembly (71). In contrast, tumor-suppressive miRNAs such as miR-223 play a critical role in restraining inflammation and tumor progression. Notably, miR-223 directly targets NLRP3 mRNA, thereby inhibiting inflammasome activation and reducing IL-1β production, highlighting its role as a negative regulator of inflammatory signaling in breast cancer (72).
ncRNAs, particularly miRNAs, serve as key regulatory nodes linking oncogenic signaling pathways with inflammasome-mediated inflammatory responses. Their ability to simultaneously modulate tumor progression and immune signaling underscores their potential as diagnostic biomarkers and therapeutic targets. Targeting ncRNA-mediated regulatory networks may therefore represent a promising strategy for modulating NLRP3 inflammasome activity and improving clinical outcomes in breast cancer, particularly in aggressive subtypes such as TNBC.
5.1. MicroRNAs interplay with TNBC and NLRP3
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression at the post-transcriptional level by binding to complementary sequences within target mRNAs, thereby inducing mRNA degradation or translational repression (17). Through these mechanisms, miRNAs play critical roles in diverse biological processes, including cell proliferation, migration, apoptosis, and immune regulation. In breast cancer, particularly in triple-negative breast cancer (TNBC), aberrant miRNA expression profiles have been extensively documented and are closely associated with tumor progression, metastasis, and therapeutic resistance (73).
Emerging evidence indicates that miRNAs serve as key regulators of inflammasome activity within the tumor microenvironment. They can modulate NLRP3 inflammasome signaling both directly, by targeting components of the inflammasome complex, and indirectly, through the regulation of upstream signaling pathways such as NF-κB, mTOR, MAPK, AMPK (74, 75), and interferon signaling cascades. In addition, miRNAs have been implicated in the regulation of pyroptosis, either promoting or suppressing this inflammatory form of programmed cell death through complex molecular networks (21).
Mechanistic studies have begun to elucidate specific miRNA-mediated regulatory circuits linking TNBC progression with inflammasome activation. For instance, miR-200b has been shown to modulate the expression of key inflammasome components, including NLRP3, ASC, caspase-1, gasdermin D (GSDMD), IL-1β, and IL-18. Its pro-pyroptotic effects are mediated through the JAZF1/NF-κB signaling axis, wherein suppression of JAZF1 relieves inhibition of NF-κB, thereby enhancing inflammasome activation. Conversely, elevated JAZF1 expression attenuates miR-200b–induced pyroptosis, highlighting a context-dependent regulatory mechanism (76).
Similarly, miR-155-5p, which is frequently upregulated in TNBC, has been implicated in modulating therapeutic responses. Inhibition of miR-155-5p using antagomirs has been shown to enhance the cytotoxic efficacy of cetuximab, promoting pyroptotic and apoptotic cell death through activation of caspase-1 and gasdermin-mediated pathways. These findings underscore the potential of miRNA modulation to sensitize TNBC cells to targeted therapies (77).
A broader spectrum of miRNAs has been linked to the regulation of NLR family members and inflammasome-associated signaling. miRNAs such as miR-125, miR-146b, miR-200 family members, miR-223-3p, miR-373, and miR-520 have been shown to regulate the expression and activity of NLRP3 and related inflammasome components. These miRNAs also intersect with key oncogenic and inflammatory signaling pathways, including NF-κB, TGF-β, and IL-6, thereby influencing TNBC cell proliferation, invasion, and immune responses (53).
Among tumor-suppressive miRNAs, miR-223 is one of the most well-characterized negative regulators of the NLRP3 inflammasome. It directly targets the 3′ untranslated region of NLRP3 mRNA, thereby inhibiting its translation and reducing the release of pro-inflammatory cytokines such as IL-1β. Similarly, miR-22 has been shown to suppress NLRP3 inflammasome assembly, leading to reduced tumor cell proliferation and downregulation of metastatic markers, including MMP2, MMP9, vimentin, and N-cadherin. miR-9 also plays a regulatory role by inhibiting NF-κB–mediated activation of the NLRP3 inflammasome, thereby reducing caspase-1 activation and downstream inflammatory cytokine production (78).
In contrast, certain miRNAs exhibit dual or context-dependent roles in TNBC progression and inflammasome regulation. For example, miR-21 has been implicated in modulating NLRP3 activity through post-translational mechanisms, including phosphorylation and ubiquitination, thereby influencing immune responses and tumor progression. Similarly, miR-205 and miR-221 have been shown to regulate tumor growth, inflammation, and metastasis through complex interactions with inflammasome signaling pathways and downstream targets such as LAMC1 and Bcl-2. Experimental studies have demonstrated that combinatorial miRNA-based strategies-such as simultaneous inhibition of oncogenic miRNAs and restoration of tumor-suppressive miRNAs-can effectively reduce TNBC cell migration, invasion, and angiogenesis. Additional miRNAs, including miR-33, miR-7-5p, and miR-22-3p, further highlight the intricate regulation of inflammasome activity. For instance, miR-33 has been reported to influence mitochondrial metabolism and reactive oxygen species production, thereby modulating NLRP3 activation and IL-1β secretion (79). Conversely, miR-223-mediated inhibition of NLRP3 has been associated with reduced tumor cell proliferation, migration, and invasion, reinforcing its tumor-suppressive function (80). Functional studies targeting miR-155 have similarly demonstrated reduced proliferative capacity and increased apoptosis in TNBC cells, accompanied by decreased production of pro-inflammatory cytokines (81).
These establishes miRNAs as central regulators of the interplay between inflammasome activation and TNBC progression. By orchestrating both inflammatory signaling and tumor cell behavior, miRNAs represent promising therapeutic targets. Strategies aimed at modulating miRNA expression-either through inhibition of oncogenic miRNAs or restoration of tumor-suppressive miRNAs-offer a novel approach for controlling NLRP3 inflammasome activity and improving therapeutic outcomes in TNBC (Figure 3).
Figure 3.

Schematic representation of microRNA-mediated regulation of NLRP3 inflammasome signaling in triple-negative breast cancer (TNBC). Oncogenic miRNAs, including miR-301b and miR-200b, promote NF-κB activation and inflammasome assembly, whereas tumor-suppressive miRNAs such as miR-223 and miR-22 inhibit NLRP3 expression or assembly. Subsequent caspase-1 activation triggers GSDMD-mediated pyroptosis and IL-1β/IL-18 release.
6. Regulatory miRNAs impacting both Wnt/β-catenin signaling and NLRP3 inflammasomes in breast cancer
MicroRNAs (miRNAs) have emerged as critical post-transcriptional regulators in breast cancer, modulating gene expression networks that govern cellular proliferation, differentiation, apoptosis, and immune responses. Increasing evidence highlights a subset of miRNAs that exert dual regulatory functions by simultaneously influencing oncogenic Wnt/β-catenin signaling and pro-inflammatory NLRP3 inflammasome activation. These two pathways represent central axes driving tumor progression, epithelial–mesenchymal transition (EMT), and immune modulation within the tumor microenvironment (82).
Among these, miR-301a is recognized as an oncogenic miRNA that is frequently dysregulated across multiple cancer types, including breast cancer. Experimental studies in ovarian cancer have demonstrated that miR-301a promotes cell proliferation and resistance to apoptosis through direct suppression of PTEN and subsequent activation of the PI3K/AKT signaling pathway (82). Given the established role of PTEN as a negative regulator of PI3K/AKT signaling and its influence on β-catenin and NF-κB pathways, it is plausible that miR-301a-mediated PTEN suppression may contribute to β-catenin stabilization and NF-κB activation in breast cancer, although direct mechanistic evidence linking all of these events in breast cancer remains limited. Furthermore, NF-κB signaling is a well-recognized priming factor for NLRP3 inflammasome activation, which can enhance IL-1β maturation and secretion, thereby fostering a pro-inflammatory tumor microenvironment (83–85). Collectively, these observations suggest that miR-301a may represent a potential molecular bridge between oncogenic signaling and inflammasome-associated inflammation; however, further breast cancer-specific studies are required to validate this mechanistic relationship.
Similarly, miR-374a, which is significantly upregulated in metastatic breast cancer, promotes tumor progression by targeting multiple negative regulators of Wnt signaling, including Wnt inhibitory factor 1 (WIF1), PTEN, and WNT5A (86). hese targets act at distinct levels of the pathway and should be distinguished. WIF1 is a secreted antagonist that sequesters Wnt ligands and thereby restrains canonical β-catenin–dependent signaling, while PTEN limits PI3K/AKT activity and indirectly favours GSK-3β–mediated β-catenin degradation; suppression of either therefore promotes β-catenin stabilization and TCF/LEF-dependent transcription. WNT5A, by contrast, is a prototypical non-canonical Wnt ligand that signals through the planar cell polarity and Wnt/Ca²+ branches and, in several contexts, antagonises canonical signaling by competing for Frizzled receptor occupancy and promoting β-catenin turnover. Loss of WNT5A consequently relieves this inhibitory constraint, contributing to canonical pathway activation indirectly rather than through direct suppression of a canonical inhibitor. The combined effect of these events is sustained β-catenin activation, enhanced invasive capacity, and induction of EMT. In addition to its effects on Wnt signaling, miR-374a indirectly amplifies inflammasome activity by modulating upstream signaling pathways. Downregulation of PTEN and WNT5A contributes to increased NF-κB activation, thereby promoting NLRP3 inflammasome priming and elevating IL-1β production. These findings highlight the role of miR-374a as a multifunctional regulator that integrates oncogenic and inflammatory signaling pathways in breast cancer (87) (Table 1).
Table 1.
Representative miRNAs linking Wnt/β-catenin and NLRP3 inflammasome pathways in breast cancer.
| miRNA | Expression in BC/TNBC | Wnt/β-catenin target | Wnt regulation | NLRP3 target/pathway | NLRP3 regulation | Direct/indirect | Experimental model | TNBC-specific evidence | Functional outcome |
|---|---|---|---|---|---|---|---|---|---|
| miR-21 | Generally upregulated; frequently associated with aggressive breast cancer | PTEN, APC and other pathway regulators | Promotes Wnt/β-catenin activity indirectly through suppression of negative regulatory mechanisms, including PTEN | A20/TNFAIP3, NF-κB/NLRP3 axis; effects are context-dependent | Can promote NLRP3 activation in macrophages through A20 suppression; tumor-derived exosomal miR-21 may suppress NLRP3 in TAMs under certain treatment conditions | Indirect in Wnt; direct for A20 in macrophages; context-dependent for NLRP3 in breast cancer | Breast cancer cells; macrophages; TAMs; animal models | Evidence exists, but NLRP3 mechanism should not be generalized specifically to TNBC without direct validation | Proliferation, survival, invasion, inflammatory/TME modulation |
| miR-155 | Upregulated in several breast cancer/TNBC models | Primarily indirect regulation of Wnt-associated regulators | Enhances oncogenic signaling and may promote β-catenin-associated tumor phenotypes | NF-κB/NLRP3 inflammatory signaling; inflammasome-associated mediators | Promotes inflammatory signaling and can enhance NLRP3-associated responses | Predominantly indirect | Breast cancer/TNBC cells; immune/inflammatory models; animal models | Yes-reported in TNBC-related studies | Proliferation, invasion, metastasis, inflammatory TME |
| miR-301a | Frequently elevated in breast cancer and associated with aggressive phenotype | PTEN | Suppression of PTEN can activate PI3K/AKT signaling and indirectly enhance β-catenin signaling | PTEN/PI3K/AKT/NF-κB inflammatory axis | May facilitate inflammasome-associated inflammatory signaling indirectly through PTEN/NF-κB regulation | Direct for PTEN; indirect for Wnt/NLRP3 | Breast cancer cell models; animal models | Evidence in aggressive/TNBC-associated breast cancer models should be identified separately from general BC evidence | Proliferation, migration, invasion and tumor progression |
| miR-374a | Upregulated in breast cancer and associated with aggressive behavior | WIF1, PTEN, WNT5A | WIF1/PTEN suppression supports enhanced canonical Wnt/β-catenin signaling; WNT5A is predominantly non-canonical | No firmly established direct NLRP3 target in breast cancer; possible inflammatory pathway crosstalk | Limited/indirect evidence; should not be presented as a direct NLRP3 regulator | Direct for WIF1/PTEN/WNT5A; indirect/limited for NLRP3 | Breast cancer cell lines; molecular/functional assays; animal models in selected studies | Evidence should be described cautiously; direct TNBC-specific Wnt–NLRP3 evidence is limited | Increased proliferation, migration, invasion and tumor progression |
| miR-223-3p | Generally considered tumor-suppressive in relevant contexts | Wnt regulation less firmly established in BC | May influence Wnt signaling indirectly, but direct breast-cancer-specific evidence is limited | NLRP3 3′-UTR | Directly suppresses NLRP3 expression by binding its 3′-UTR | Direct for NLRP3; limited/indirect for Wnt | Macrophages/immune cells; inflammatory models; cancer-related models | Direct TNBC-specific dual-pathway evidence remains limited | Reduced inflammasome activation and inflammatory signaling |
| miR-296-5p | Reported as tumor-suppressive/downregulated in some breast cancer contexts | Wnt-associated regulators; evidence varies by model | Potential suppression of oncogenic Wnt signaling, but mechanistic evidence requires careful model-specific interpretation | NLRP3/inflammatory signaling | Evidence linking miR-296-5p directly to NLRP3 is currently limited | Limited/indirect | Breast cancer cells and experimental cancer models | Limited direct TNBC-specific evidence | May reduce proliferation, invasion and inflammatory signaling |
| miR-590-5p | Reported as dysregulated in breast cancer | PITX2/Wnt-associated signaling in reported studies | Reported to influence Wnt/β-catenin-associated tumor behavior | NLRP3 association is not sufficiently established | Limited/insufficient direct evidence | Context-dependent; insufficient evidence for direct dual regulation | Breast cancer cell models; experimental models | TNBC-specific evidence should not be claimed without direct supporting study | Potential effects on proliferation, migration and invasion |
| miR-34a | Frequently reduced in breast cancer; generally, tumor-suppressive | Wnt pathway components/regulators in different cancer contexts | Can suppress oncogenic Wnt/β-catenin signaling through regulation of pathway components | NF-κB/inflammatory and inflammasome-associated pathways | Potential suppression of inflammatory signaling; direct NLRP3 regulation in breast cancer requires further validation | Indirect/limited | Breast cancer cells; animal models; immune/inflammatory models | TNBC relevance is reported for miR-34a biology, but direct miR-34a–Wnt–NLRP3 linkage remains insufficiently established | Reduced proliferation, invasion, stemness and inflammatory signaling |
6.1. Crosstalk dynamics between Wnt and NLRP3 pathways
Accumulating evidence supports the existence of a dynamic and bidirectional crosstalk between the Wnt/β-catenin signaling pathway and the NLRP3 inflammasome, with microRNAs (miRNAs) serving as key modulators of this interaction. At the mechanistic level, direct protein–protein interactions provide a functional link between these pathways (88, 89). Notably, β-catenin has been shown to physically associate with NLRP3, thereby enhancing its interaction with the adaptor protein ASC and promoting inflammasome assembly. This interaction facilitates caspase-1 activation and the subsequent maturation of pro-inflammatory cytokines, including IL-1β. Consequently, elevated β-catenin levels can potentiate inflammasome activity, establishing a positive feedback loop that amplifies inflammatory signaling within the tumor microenvironment (90).
Conversely, inflammasome-derived cytokines can influence Wnt signaling outputs. IL-1β, a key effector of NLRP3 activation, has been implicated in the activation of NF-κB signaling, which in turn can upregulate the expression of Wnt ligands, receptors, and downstream proliferative genes. In breast cancer, particularly within inflammatory tumor microenvironments, IL-1β signaling has been associated with enhanced nuclear localization of β-catenin, suggesting that inflammasome activation can reinforce Wnt-driven transcriptional programs (91).
miRNAs introduce an additional layer of regulatory complexity by coordinating transcriptional and post-transcriptional feedback between these pathways.
The biological effects of miRNAs on inflammasome signaling are strongly influenced by cellular context. Breast tumors consist not only of malignant epithelial cells but also of tumor-associated macrophages, fibroblasts, lymphocytes, myeloid-derived suppressor cells, and other stromal populations. These cells may express or exchange miRNAs through intracellular mechanisms and extracellular vesicles, resulting in cell-type-specific effects. Therefore, observations made in macrophages or systemic inflammatory models should not automatically be extrapolated to malignant breast epithelial cells.
This distinction is particularly relevant for miR-21. Rather than acting as a uniform activator or inhibitor of NLRP3 signaling, the effect of miR-21 appears to depend on the producing cell, recipient cell, inflammatory stimulus, and experimental model. Accordingly, miR-21 is considered here a context-dependent regulator of inflammasome-associated signaling rather than a universal positive regulator of NLRP3 in breast cancer. Inflammatory signaling mediated by NF-κB frequently induces the expression of oncogenic miRNAs, including miR-21 and miR-155. These miRNAs amplify Wnt/β-catenin signaling by targeting negative regulators such as PTEN, while simultaneously modulating inflammasome activity (21). For example, miR-155 has been shown to suppress the transcription factor FOXO3a, a negative regulator of IL-1β expression, thereby enhancing inflammasome-mediated cytokine production. Through these mechanisms, inflammatory stimuli can propagate oncogenic signaling via miRNA-mediated feedback loops (92).
Reciprocally, Wnt/β-catenin signaling can modulate miRNA expression profiles. Activation of β-catenin–dependent transcription through TCF/LEF factors has been reported to repress tumor-suppressive miRNAs, such as miR-34a, thereby relieving inhibitory constraints on both inflammasome components and oncogenic signaling pathways. This bidirectional regulation underscores the intricate integration of signaling networks governing tumor progression (93).
Within this regulatory framework, distinct classes of miRNAs exert opposing effects on pathway activity. Tumor-suppressive miRNAs, such as miR-223-3p, inhibit inflammasome activation by directly targeting NLRP3 mRNA and simultaneously attenuating β-catenin signaling (94). In contrast, oncogenic miRNAs, including miR-301a, promote both β-catenin stabilization and inflammasome activation through suppression of PTEN and subsequent activation of NF-κB signaling, leading to increased IL-1β production. These miRNAs thus function as molecular switches that fine-tune the balance between oncogenic signaling and inflammatory responses (95).
Collectively, the crosstalk between Wnt/β-catenin signaling and the NLRP3 inflammasome is characterized by interconnected feedback loops that can be either self-reinforcing or self-limiting. A notable example is the double-negative feedback loop involving miR-223-3p and NF-κB signaling, wherein miR-223-3p suppresses NLRP3 expression, while NF-κB activity downstream of inflammasome activation represses miR-223-3p expression. Such regulatory circuits confer switch-like behavior to inflammatory responses and contribute to the dynamic adaptation of tumor cells within the microenvironment. Understanding these miRNA-mediated regulatory networks is essential for elucidating how oncogenic signaling and chronic inflammation co-evolve during breast cancer progression. Targeting these interconnected pathways may provide novel therapeutic opportunities to simultaneously disrupt tumor-promoting signaling and inflammatory circuits. The interactions described in this section are supported by evidence of unequal strength, and this should be made explicit before the framework is considered established. The physical association between β-catenin and NLRP3, which constitutes the mechanistic anchor of the proposed module, was demonstrated in macrophage systems and has not been shown in breast cancer cells; it is therefore mechanistically informative but extrapolative with respect to breast tumour biology. The reciprocal limb of the circuit, whereby IL-1β reinforces Wnt signaling through NF-κB, is supported largely by studies in inflammatory and other cancers, with correlative rather than causal evidence in breast cancer (Figure 4).
Figure 4.

Schematic representation of crosstalk between Wnt/β-catenin and NLRP3 inflammasome signaling pathways. Wnt activation stabilizes β-catenin, promoting TCF/LEF-mediated transcription associated with EMT and inflammation. PTEN, APC, and microRNAs modulate pathway interactions, while NF-κB drives NLRP3 and pro-IL-1β expression. Inflammasome activation triggers caspase-1-dependent IL-1β maturation and secretion, enhancing tumor progression.
7. Therapeutic implications
The coordinated interplay between Wnt/β-catenin signaling and NLRP3 inflammasome activation in breast cancer presents a potential opportunity for the development of integrated therapeutic strategies, although it should be emphasised at the outset that no agent targeting this axis has yet been evaluated in a clinical trial in breast cancer. Targeting these interconnected pathways has gained increasing attention, with several pharmacological agents including phytochemicals under investigation (96–98). Inhibitors of Wnt signaling, including Porcupine inhibitors, Frizzled (FZD) receptor antagonists, and β-catenin–TCF interaction disruptors, have attenuated oncogenic signaling in preclinical models; among these, Porcupine inhibitors and FZD-directed antibodies have progressed to early-phase clinical evaluation in solid tumours, whereas β-catenin–TCF disruptors remain at the preclinical stage. In parallel, NLRP3 inflammasome inhibitors such as MCC950 and β-sulfonyl nitrile–based compounds have been shown to suppress inflammasome activation and downstream inflammatory responses in cell-based and animal studies, but have not been tested clinically in oncology indications (99).
Emerging preclinical evidence suggests that combinatorial targeting of these pathways may yield synergistic therapeutic effects. Inhibition of Wnt signaling can reduce β-catenin–mediated enhancement of inflammasome assembly, thereby indirectly limiting NLRP3 activation. Conversely, blockade of NLRP3 activity may disrupt IL-1β–driven feedback loops that reinforce Wnt/β-catenin signaling. This bidirectional targeting approach has the potential to simultaneously suppress tumor proliferation and tumor-promoting inflammation, offering theoretical advantages over single-pathway inhibition (100), it should be noted, however, that this rationale is derived from mechanistic studies rather than from combination efficacy data, and that no such combination has been formally tested in breast cancer models.
An additional strategy involves the modulation of microRNAs (miRNAs) that co-regulate both pathways. Restoration of tumor-suppressive miRNAs, such as miR-223-3p and miR-590-5p, through miRNA mimics may concurrently inhibit Wnt signaling and NLRP3 inflammasome activation (100). Conversely, targeting oncogenic miRNAs, including miR-21 and miR-155, using antagomiRs or miRNA sponges could restore the expression of key negative regulators such as PTEN and SFRP1, thereby attenuating β-catenin signaling and normalizing inflammasome activity (101). These proposals are supported by in vitro and, in some cases, murine data, but remain hypothetical in the clinical setting: miRNA-directed therapeutics in general remain at an early developmental stage across oncology, and none has been advanced to clinical evaluation in breast cancer. These RNA-based approaches nonetheless offer a means to modulate multiple oncogenic and inflammatory pathways simultaneously.
From a biomarker perspective, specific miRNA expression profiles may serve as indicators of pathway activity and disease state. For example, elevated levels of miR-301a and miR-374a, coupled with reduced expression of miR-223-3p, may identify tumors characterized by concurrent hyperactivation of Wnt signaling and inflammasome pathways. Such signatures could facilitate patient stratification and guide the selection of combination therapies, although this composite signature is proposed here on mechanistic grounds and has not been evaluated in a patient cohort. Retrospective analyses of existing breast cancer datasets, followed by prospective validation, would be required before such profiles could inform treatment selection, and further studies are needed to determine how molecular subtypes of breast cancer, such as hormone receptor–positive versus triple-negative disease, influence the Wnt–inflammasome axis.
Finally, the complexity of this regulatory network suggests the involvement of additional modulators, including long non-coding RNAs and epigenetic mechanisms, which remain to be fully elucidated. Given the critical role of the tumor microenvironment in shaping disease progression, therapeutic strategies that incorporate immune modulation are also of interest. In particular, combinations of immune checkpoint inhibitors with inflammasome-targeting agents may enhance anti-tumor immune responses while mitigating tumor-promoting inflammation; immune checkpoint inhibitors are established in clinical practice for triple-negative breast cancer, but their combination with inflammasome-directed agents has not been assessed clinically.
Several considerations temper the proposal of combinatorial targeting. Direct evidence of synergy is currently absent: the rationale rests on the reciprocal coupling between the two pathways rather than on combination studies, and it remains possible that the effects would prove additive, or that inhibition of one arm would be compensated by the other, as has been observed with other feedback-coupled oncogenic networks. Formal evaluation using fixed-ratio combination designs and established synergy metrics in breast cancer cell lines and xenograft models is therefore a necessary first step. Toxicity presents a further constraint, since the profiles of the two classes of agent are distinct and may not combine favourably: Wnt pathway inhibition carries dose-limiting gastrointestinal, skeletal, and haematopoietic toxicity arising from impaired tissue homeostasis, whereas sustained NLRP3 blockade may compromise innate host defence, so that combining the two could narrow an already restricted therapeutic window and may require intermittent or pulsed rather than continuous dosing. Sequencing is likewise unresolved and mechanistically consequential. Because β-catenin promotes inflammasome assembly while IL-1β reinforces Wnt signaling, the order of intervention may determine outcome: upstream Wnt inhibition might be expected to reduce inflammasome activity indirectly, potentially permitting lower doses of an NLRP3-directed agent, whereas initial inflammasome blockade would not be expected to limit ligand-driven Wnt activation. Whether concurrent or sequential administration is preferable can only be resolved experimentally.
With respect to patient selection, the tumours most likely to benefit would be those in which both arms are demonstrably co-activated - for example, nuclear β-catenin localisation together with elevated caspase-1 or IL-1β - rather than breast cancer unselected by pathway status. Triple-negative disease is the most plausible enrichment strategy on current evidence, though this remains to be tested. Development of such a companion biomarker strategy should precede, rather than follow, evaluation of these combinations in patients.
7.1. Diagnostic and prognostic biomarkers
Components of the Wnt/β-catenin–NLRP3 inflammasome axis, including microRNAs (miRNAs) and pro-inflammatory cytokines, have emerged as promising candidates for diagnostic and prognostic biomarker development in breast cancer. These molecules reflect the underlying activity of oncogenic and inflammatory signaling pathways and may provide valuable insights into disease progression, therapeutic response, and patient stratification. Oncogenic miRNAs are frequently associated with adverse clinical outcomes. Elevated expression of miR-301a and miR-21 in tumor tissues or circulating fluids has been consistently correlated with poor prognosis and reduced overall survival in breast cancer patients. In particular, increased miR-301a levels have been linked to enhanced tumor invasiveness and metastatic potential, likely due to its role in activating Wnt/β-catenin signaling and promoting tumor progression (102).
Conversely, tumor-suppressive miRNAs, including miR-223-3p and miR-34a, are generally associated with favorable clinical outcomes. Higher expression levels of these miRNAs have been correlated with reduced tumor aggressiveness and improved responsiveness to therapy (103). Experimental studies further support their protective role; for instance, overexpression of miR-223-3p has been shown to suppress tumor growth in preclinical models, suggesting that reduced miR-223-3p expression may serve as a biomarker of aggressive disease phenotypes (94).
In addition to miRNAs, inflammasome-associated cytokines provide important prognostic information. Elevated levels of IL-1β and IL-18 within the tumor microenvironment are indicative of a pro-inflammatory and pro-metastatic niche. Clinical and experimental studies, particularly in triple-negative breast cancer (TNBC), have demonstrated that increased expression of inflammatory cytokines such as TNF-α and IL-1β correlates with rapid disease progression, enhanced metastatic potential, and poor clinical outcomes (104).
The integration of Wnt signaling and inflammasome markers further enhances prognostic precision. Tumors characterized by concurrent activation of Wnt/β-catenin signaling-evidenced by nuclear localization of β-catenin-and elevated inflammasome activity, reflected by increased caspase-1 or IL-1β levels, may represent a high-risk subgroup. miRNA expression profiles may complement cytokine-based biomarkers; a signature comprising elevated miR-301a and miR-374a alongside reduced miR-223-3p expression has been proposed here on mechanistic grounds as an indicator of simultaneous Wnt and NLRP3 pathway activation, but it has not been assessed in any patient cohort and should be regarded as a hypothesis requiring retrospective validation in existing breast cancer datasets followed by prospective evaluation. Advances in liquid biopsy technologies have facilitated the non-invasive detection of these biomarkers in circulating blood. Exosomal miRNAs, such as miR-21, miR-155, and miR-223, can reflect tumor-specific molecular alterations and serve as minimally invasive indicators of disease state. Similarly, circulating IL-1β levels or ASC specks-indicative of active inflammasome signaling-may provide insights into systemic inflammatory status and tumor activity. The integration of these circulating biomarkers holds significant potential for real-time monitoring of disease progression and therapeutic response (105).
8. Current limitations and future clinical translation
Despite growing evidence supporting the therapeutic relevance of the Wnt/β-catenin–NLRP3 inflammasome axis in breast cancer, its clinical translation remains at an early stage. Most mechanistic insights have been derived from in vitro studies, animal models, and analyses of patient-derived datasets, while direct clinical evidence demonstrating the efficacy of targeting this regulatory network in breast cancer is still limited. Consequently, the therapeutic strategies discussed above should be interpreted with caution until validated through well-designed clinical trials.
One of the major challenges is the safe and efficient delivery of miRNA-based therapeutics. Although miRNA mimics and antagomiRs offer the ability to simultaneously regulate multiple oncogenic and inflammatory pathways, their clinical application is hindered by poor stability in circulation, rapid nuclease-mediated degradation, limited tumor-specific uptake, and potential off-target effects. Furthermore, the broad regulatory nature of miRNAs increases the possibility of unintended modulation of non-target genes, raising concerns regarding toxicity and long-term safety. Advances in lipid nanoparticles, polymeric nanocarriers, exosomes, and ligand-directed delivery systems have improved nucleic acid delivery; however, these technologies require further optimization before routine clinical application in breast cancer.
Similarly, pharmacological inhibition of the Wnt/β-catenin pathway presents significant challenges because this signaling cascade is essential for normal tissue homeostasis, stem cell maintenance, and intestinal epithelial regeneration. Systemic inhibition may therefore produce dose-limiting toxicities, including gastrointestinal dysfunction, impaired bone remodeling, and hematopoietic abnormalities. Although several Porcupine inhibitors, Frizzled receptor antagonists, and β-catenin inhibitors have entered early-phase clinical studies in solid tumors, none has yet demonstrated sufficient efficacy and safety to become standard therapy for breast cancer.
Targeting the NLRP3 inflammasome also requires careful consideration of immune-related adverse effects. While inhibitors such as MCC950 effectively suppress inflammasome activation in preclinical models, chronic inhibition of innate immune signaling may compromise host defense against infections and alter normal tissue repair processes. Moreover, the dual role of inflammation in cancer complicates therapeutic intervention, as inflammasome signaling may exert both tumor-promoting and context-dependent tumor-suppressive functions depending on disease stage and the composition of the tumor microenvironment.
Another important limitation is the lack of validated predictive biomarkers capable of identifying patients most likely to benefit from therapies targeting the Wnt–NLRP3 axis. Breast cancer exhibits substantial molecular and immunological heterogeneity across hormone receptor-positive, HER2-positive, and triple-negative subtypes, suggesting that therapeutic responses may differ considerably. Therefore, prospective clinical studies integrating genomic, transcriptomic, proteomic, and circulating biomarker analyses are essential for patient stratification and treatment optimization. Future research should also focus on rational combination strategies incorporating targeted therapies, immunotherapy, and nanotechnology-based delivery systems to improve efficacy while minimizing toxicity. Such multidisciplinary approaches will be critical for translating mechanistic discoveries into clinically meaningful therapeutic interventions.
Among these translational barriers, those affecting miRNA-directed therapeutics warrant particular attention, since experience from the first candidates to reach human testing is instructive. The miR-34a mimic MRX34 entered a phase I trial in advanced solid tumours but was terminated following serious immune-mediated adverse events, illustrating that systemic delivery of a miRNA mimic can provoke unanticipated innate immune activation. This consideration is particularly relevant to the axis discussed here, since mimics intended to dampen inflammasome signaling could, through nucleic acid sensing, produce the opposite effect. The antagomiR miravirsen, directed against miR-122, demonstrated that miRNA inhibition is achievable in humans, but its success depended on hepatic tropism that is not readily reproduced in breast tumours. For the miRNAs discussed in this review, no candidate has entered clinical evaluation in breast cancer, and the principal barriers remain tumour-selective delivery, dose control sufficient to avoid modulating the same miRNA in normal tissue, and the pleiotropy inherent to miRNAs that regulate hundreds of transcripts. Addressing these issues will require chemically stabilised constructs, ligand-directed or exosome-based carriers, and, importantly, pharmacodynamic biomarkers capable of confirming target engagement at both the Wnt and inflammasome arms before efficacy can be meaningfully assessed.
9. Conclusion
The evidence reviewed here indicates that Wnt/β-catenin signaling and NLRP3 inflammasome activation in breast cancer may constitute a bidirectionally coupled module rather than independent oncogenic and inflammatory axes, linked by the reported association of β-catenin with NLRP3 and by IL-1β–dependent induction of Wnt signaling through NF-κB, with a defined subset of miRNAs acting on both arms. Four questions require resolution before this framework can be considered established. First, the β-catenin–NLRP3 association has been characterised in macrophage systems and has not been demonstrated in breast tumour cells. Co-immunoprecipitation and proximity ligation analyses in breast cancer cell lines and patient-derived tissue, with domain mapping of the interacting regions, are required to determine whether the interaction occurs in the epithelial compartment. Second, the majority of miRNA–target relationships described here derive from correlative expression data and reporter assays. Endogenous editing of individual miRNAs or their binding sites, combined with target rescue, is necessary to establish whether dual-pathway regulation is direct and whether it operates at physiological expression levels. Third, the cellular compartment in which the module functions have not been defined. Given that tumour-associated macrophages represent a principal source of IL-1β in breast tumours, coupling between the two arms may be paracrine rather than cell-intrinsic. Conditional deletion of Nlrp3 or Ctnnb1 in defined compartments, together with single-cell and spatial transcriptomic analysis of human tumours, would distinguish these possibilities. Fourth, the clinical significance of concurrent pathway activation is unknown. Retrospective analysis of existing breast cancer cohorts, correlating nuclear β-catenin localisation with inflammasome component expression and circulating miRNA profiles, would provide an initial assessment, followed by prospective validation. Resolution of these questions will determine whether the miRNA–Wnt–NLRP3 axis represents a therapeutically actionable module or a group of correlated but mechanistically separable processes. Until such data are available, the strategies described in this review should be regarded as hypotheses for experimental testing rather than as established translational priorities.
Acknowledgments
The authors express their heartfelt gratitude to the Institute of Medical Science-BHU, Varanasi, for providing financial and other support for carrying out this research. Furthermore, the authors acknowledge the Banaras Hindu University, for awarding a Ph.D. fellowship to author Muskan & Shalini. All figures were created using templates available on BioRender.com.
Funding Statement
The author(s) declared that financial support was not received for this work and/or its publication.
Footnotes
Edited by: Dirk Geerts, GenDx, Netherlands
Reviewed by: Anjali Ravi, Bharathiar University, India
Ehsan Mehrtabar, Tehran University of Medical Sciences, Iran
Author contributions
MB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. SM: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. SK: Writing – review & editing. JK: Writing – review & editing. SPM: Conceptualization, Funding acquisition, Investigation, Project administration, Supervision, Validation, Writing – review & editing.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- 1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. (2022) 66:15–23. doi: 10.1016/j.breast.2022.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Seely JM. Progress and remaining gaps in the early detection and treatment of breast cancer. Curr Oncol. (2023) 30:3201–5. doi: 10.3390/curroncol30030242 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Sharma A, Soni N, Chaudhary M, Jia J, Bissa B. Deciphering the relevance of dead box RNA helicases in gliomagenesis and autophagy. Hum Cell. (2025) 39:16. doi: 10.1007/s13577-025-01329-1 [DOI] [PubMed] [Google Scholar]
- 4. Reytor-González C, Simancas-Racines D, Román-Galeano NM, Campuzano-Donoso M, Carella AM, Zambrano-Villacres R, et al. Obesity and breast cancer: exploring the nexus of chronic inflammation, metabolic dysregulation, and nutritional strategies. Food Agric Immunol. (2025) 36:2521270. doi: 10.1080/09540105.2025.252127037339054 [DOI] [Google Scholar]
- 5. Sharma A, Shukla A, Raut SS, Singh A, Mishra A. Transcriptomic profiling of breast cancer subtypes identifies “FANCE” as universal and subtype-specific biomarkers. In Silico Res Biomedicine. (2026) 2:100304. doi: 10.1016/j.insi.2026.10030442574925 [DOI] [Google Scholar]
- 6. Sharma A, Raut SS, Shukla A, Gupta S, Mishra A, Singh A. From tissue architecture to clinical insights: spatial transcriptomics in solid tumor studies. Semin Oncol. (2025) 52:152389. doi: 10.1016/j.seminoncol.2025.152389 [DOI] [PubMed] [Google Scholar]
- 7. Far NP, Varnousafaderani MH, Faghihkhorasani F, Etemad S, Abdulwahid A-H, Bakhtiarinia N, et al. . doi: 10.1111/bph.17352 [DOI]
- 8. Sharma A, Raut SS, Dhikale P, Khushboo, Mishra A. Navigating the landscape of cancer-induced thrombocytopenia: current challenges and emerging advances. In: Verma P, editor. Industrial Microbiology and Biotechnology. Springer Nature Singapore, Singapore: (2024). p. 435–63. doi: 10.1007/978-981-97-6270-5_14 [DOI] [Google Scholar]
- 9. Biasizzo M, Kopitar-Jerala N. Interplay between NLRP3 inflammasome and autophagy. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.591803 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Jo E-K, Kim JK, Shin D-M, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. (2016) 13:148–59. doi: 10.1038/cmi.2015.95 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Faria SS, Costantini S, Di Gennaro E, de Lima VCC, Andrade VP, de Pádua C, et al. Analysis of the NLRP3 inflammasome components expression in triple-negative breast cancer patients with and without BRCA1 mutations. Sci Rep. (2026) 16:15316. doi: 10.1038/s41598-026-43392-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Mahanujam A. The role of beta-catenin and the Wnt signalling pathway in breast cancer initiation, progression and metastasis: a literature review. Undergraduate Res Natural Clin Sci Technol J. (2025) 9:1–9. doi: 10.26685/urncst.715 [DOI] [Google Scholar]
- 13. Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Sig Transduct Target Ther. (2025) 10:106. doi: 10.1038/s41392-025-02142-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Luo B, Li L, Huang L, Deng L. Curcumin ameliorates microplastic-induced testicular inflammatory damage by suppressing NLRP3 and WNT/β-catenin signaling pathway activation. Curr Sci. (2025) 5:3363–78. doi: 10.52845/CS/2025-5-4-3 [DOI] [Google Scholar]
- 15. Sharma A, Raut SS, Shukla A, Singh A, Mishra A. Therapeutic targeting of the mitochondrial dysfunction-PANoptosis axis: mechanistic insights and emerging strategies. Trans Res. (2026) 291:1–39. doi: 10.1016/j.trsl.2026.03.004 [DOI] [PubMed] [Google Scholar]
- 16. Zhou M, Gao Z, Sun J, Long W, Zhou J, Fang W, et al. Aquaporin-1 stabilizes β-catenin to promote NLRP3 inflammasome-mediated pyroptosis in rheumatoid arthritis. Apoptosis. (2026) 31:74. doi: 10.1007/s10495-026-02289-z [DOI] [PubMed] [Google Scholar]
- 17. Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genom Proteom Bioinform. (2017) 15:177–86. doi: 10.1016/j.gpb.2016.12.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem. (2013) 54:29–38. doi: 10.1042/bse0540029 [DOI] [PubMed] [Google Scholar]
- 19. Nogueras Pérez R, Heredia-Nicolás N, de Lara-Peña L, López de Andrés J, Marchal JA, Jiménez G, et al. Unraveling the potential of miRNAs from CSCs as an emerging clinical tool for breast cancer diagnosis and prognosis. Int J Mol Sci. (2023) 24:16010. doi: 10.3390/ijms242116010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Jafari A, Karimabadi K, Rahimi A, Rostaminasab G, Khazaei M, Rezakhani L, et al. The emerging role of exosomal miRNAs as biomarkers for early cancer detection: a comprehensive literature review. Technol Cancer Res Treat. (2023) 22:15330338231205999. doi: 10.1177/15330338231205999 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Stămat L-R, Dinescu S, Costache M. Regulation of inflammasome by microRNAs in triple-negative breast cancer: new opportunities for therapy. Int J Mol Sci. (2023) 24:3245. doi: 10.3390/ijms24043245 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Sharma A, Raut SS, Shukla A, Singh A, Mishra A. Bibliometric analysis of PANoptosis research: global trends, research hotspots, and emerging directions. Cell Death. (2026) 2:100024. doi: 10.1016/j.celld.2026.10002442574925 [DOI] [Google Scholar]
- 23. Sahoo M, Ceballos-Olvera I, del Barrio L, Re F. Role of the inflammasome, IL-1β, and IL-18 in bacterial infections. Sci World J. (2011) 11:212680. doi: 10.1100/2011/212680 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Faria SS, Costantini S, de Lima VCC, de Andrade VP, Rialland M, Cedric R, et al. NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J BioMed Sci. (2021) 28:26. doi: 10.1186/s12929-021-00724-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Raut PK, Kim S-H, Choi DY, Jeong G-S, Park P-H. Growth of breast cancer cells by leptin is mediated via activation of the inflammasome: critical roles of estrogen receptor signaling and reactive oxygen species production. Biochem Pharmacol. (2019) 161:73–88. doi: 10.1016/j.bcp.2019.01.006 [DOI] [PubMed] [Google Scholar]
- 26. Papafragkos I, Grigoriou M, Boon L, Kloetgen A, Hatzioannou A, Verginis P. Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.889075 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. (2023) 41:301–16. doi: 10.1146/annurev-immunol-081022-021207 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature. (2023) 613:595–600. doi: 10.1038/s41586-022-05570-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Theodoropoulou K, Spel L, Zaffalon L, Delacrétaz M, Hofer M, Martinon F. NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome. J Allergy Clin Immunol. (2023) 151:222–232.e9. doi: 10.1016/j.jaci.2022.08.019 [DOI] [PubMed] [Google Scholar]
- 30. Vande Walle L, Lamkanfi M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. (2024) 23:43–66. doi: 10.1038/s41573-023-00822-2 [DOI] [PubMed] [Google Scholar]
- 31. MacDonald JA, Wijekoon CP, Liao K-C, Muruve DA. Biochemical and structural aspects of the ATP-binding domain in inflammasome-forming human NLRP proteins. IUBMB Life. (2013) 65:851–62. doi: 10.1002/iub.1210 [DOI] [PubMed] [Google Scholar]
- 32. Li D, Wu M. Pattern recognition receptors in health and diseases. Sig Transduct Target Ther. (2021) 6:291. doi: 10.1038/s41392-021-00687-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Gritsenko A, Yu S, Martin-Sanchez F, Diaz-del-Olmo I, Nichols E-M, Davis DM, et al. Priming is dispensable for NLRP3 inflammasome activation in human monocytes in vitro. Front Immunol. (2020) 11. doi: 10.3389/fimmu.2020.565924 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Couillin I, Gombault A, Baron L. ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol. (2013) 3. doi: 10.3389/fimmu.2012.00414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Jin M, Fang J, Wang J, Shao X, Xu S, Liu P, et al. Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharmacol Sin. (2023) 44:2358–75. doi: 10.1038/s41401-023-01123-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Agrawal I, Jha S. Comprehensive review of ASC structure and function in immune homeostasis and disease. Mol Biol Rep. (2020) 47:3077–96. doi: 10.1007/s11033-020-05345-2 [DOI] [PubMed] [Google Scholar]
- 37. Santagostino SF, Assenmacher C-A, Tarrant JC, Adedeji AO, Radaelli E. Mechanisms of regulated cell death: current perspectives. Vet Pathol. (2021) 58:596–623. doi: 10.1177/03009858211005537 [DOI] [PubMed] [Google Scholar]
- 38. Sharma A, Raut SS, Shukla A, Gupta S, Singh A, Mishra A. DDX3X dynamics, glioblastoma’s genetic landscape, therapeutic advances, and autophagic interplay. Med Oncol. (2024) 41:258. doi: 10.1007/s12032-024-02525-z [DOI] [PubMed] [Google Scholar]
- 39. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. (2009) 30:383–91. doi: 10.1016/j.it.2009.05.007 [DOI] [PubMed] [Google Scholar]
- 40. Tang T, Li P, Zhou X, Wang R, Fan X, Yang M, et al. The E3 ubiquitin ligase TRIM65 negatively regulates inflammasome activation through promoting ubiquitination of NLRP3. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.741839 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol. (2024) 17:46. doi: 10.1186/s13045-024-01563-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Khan MU, Mansur H, Asmat S, Chaudry MU, Umair M, Mazhar N. Prognostic significance of immunohistochemical expression of cyclin D1 and β-catenin in invasive ductal carcinoma (IDC). Azerbaijan Pharm Pharmacotherapy J. (2024) 23:125–31. doi: 10.61336/appj/24-04-1542710276 [DOI] [Google Scholar]
- 43. Chafey P, Finzi L, Boisgard R, Caüzac M, Clary G, Broussard C, et al. Proteomic analysis of β‐catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics. (2009) 9(15):3889–3900. doi: 10.1002/pmic.200800609 [DOI] [PubMed] [Google Scholar]
- 44. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. (2007) 3:30–8. doi: 10.1007/s12015-007-0006-6 [DOI] [PubMed] [Google Scholar]
- 45. Ren Q, Chen J, Liu Y. LRP5 and LRP6 in Wnt signaling: similarity and divergence. Front Cell Dev Biol. (2021) 9. doi: 10.3389/fcell.2021.670960 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Luo C, Li N, Lu B, Cai J, Lu M, Zhang Y, et al. Global and regional trends in incidence and mortality of female breast cancer and associated factors at national level in 2000 to 2019. Chin Med J. (2022) 135:42–51. doi: 10.1097/CM9.0000000000001814 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Castaño Z, San Juan BP, Spiegel A, Pant A, DeCristo MJ, Laszewski T, et al. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol. (2018) 20:1084–97. doi: 10.1038/s41556-018-0173-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Erasha AM, EL-Gendy H, Aly AS, Fernández-Ortiz M, Sayed RKA. The role of the tumor microenvironment (TME) in advancing cancer therapies: immune system interactions, tumor-infiltrating lymphocytes (TILs), and the role of exosomes and inflammasomes. Int J Mol Sci. (2025) 26:2716. doi: 10.3390/ijms26062716 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Li W, Qu J, Li W, Cao Y, Xu R, Xu L. Targeting obesity and adipokine signaling in the breast cancer microenvironment for enhanced tumor therapy. Nanoscale. (2026) 18(24):12603–12644. doi: 10.1039/D5NR05009J [DOI] [PubMed] [Google Scholar]
- 50. Chen Q, Lei JH, Bao J, Wang H, Hao W, Li L, et al. BRCA1 deficiency impairs mitophagy and promotes inflammasome activation and mammary tumor metastasis. Advanced Science. (2020) 7(6):1903616. doi: 10.1002/advs.201903616 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Hoss F, Rodriguez-Alcazar JF, Latz E. Assembly and regulation of ASC specks. Cell Mol Life Sci. (2017) 74:1211–29. doi: 10.1007/s00018-016-2396-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manage Res. (2022) 14:1–17. doi: 10.2147/CMAR.S316700 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Wang X, Lin J, Wang Z, Li Z, Wang M. Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer. Discov Onc. (2023) 14:93. doi: 10.1007/s12672-023-00701-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Chou W-C, Jha S, Linhoff MW, Ting J-Y. The NLR gene family: from discovery to present day. Nat Rev Immunol. (2023) 23:635–54. doi: 10.1038/s41577-023-00849-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Aranda-Rivera AK, Srivastava A, Cruz-Gregorio A, Pedraza-Chaverri J, Mulay SR, Scholze A. Involvement of inflammasome components in kidney disease. Antioxidants. (2022) 11:246. doi: 10.3390/antiox11020246 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Li R, Wang Y, Xie M. Tumor microenvironment and key signaling pathways in breast cancer progression and therapy resistance: a review. Biomol BioMed. (2026) 26:1461–75. doi: 10.17305/bb.2026.13708 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.954992 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Lin T-Y, Tsai M-C, Tu W, Yeh H-C, Wang S-C, Huang S-P, et al. Role of the NLRP3 inflammasome: insights into cancer hallmarks. Front Immunol. (2021) 11. doi: 10.3389/fimmu.2020.610492 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Tengesdal IW, Dinarello A, Powers NE, Burchill MA, Joosten LAB, Marchetti C, et al. Tumor NLRP3-derived IL-1β drives the IL-6/STAT3 axis resulting in sustained MDSC-mediated immunosuppression. Front Immunol. (2021) 12. doi: 10.3389/fimmu.2021.661323 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Wang J, Wu S-G. Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer: Targets Ther. (2023) 15:721–30. doi: 10.2147/BCTT.S432526 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Raut SS, Sharma A, Yadav R, Kumar S, Shukla A, Singh A, et al. Biological green synthesis of nanoparticles: a sustainable platform for agricultural, environmental, food, and cosmetic applications. J Environ Chem Eng. (2026) 14:121102. doi: 10.1016/j.jece.2026.12110242574925 [DOI] [Google Scholar]
- 62. Raut SS, sharma A, Mishra A. A decade of bibliometric and biotechnological advances in microbial polyhydroxyalkanoate (PHA) for biomedical applications: developments in economical production, biosynthetic pathways, physicochemical properties, and therapeutic potential: a review. Int J Biol Macromol. (2026) 337:149477. doi: 10.1016/j.ijbiomac.2025.149477 [DOI] [PubMed] [Google Scholar]
- 63. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. (2016) 16:407–20. doi: 10.1038/nri.2016.58 [DOI] [PubMed] [Google Scholar]
- 64. Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, et al. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget. (2016) 7:56295–308. doi: 10.18632/oncotarget.10787 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Micheel J, Safrastyan A, Wollny D. Advances in non-coding RNA sequencing. Non-Coding RNA. (2021) 7:70. doi: 10.3390/ncrna7040070 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Morselli M, Dieci G. Epigenetic regulation of human non-coding RNA gene transcription. Biochem Soc Trans. (2022) 50:723–36. doi: 10.1042/BST20210860 [DOI] [PubMed] [Google Scholar]
- 67. Tian T, Wang M, Lin S, Guo Y, Dai Z, Liu K, et al. The impact of lncRNA dysregulation on clinicopathology and survival of breast cancer: a systematic review and meta-analysis. Mol Ther Nucleic Acids. (2018) 12:359–69. doi: 10.1016/j.omtn.2018.05.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Wei F, Cao C, Xu X, Wang J. Diverse functions of miR-373 in cancer. J Transl Med. (2015) 13:162. doi: 10.1186/s12967-015-0523-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Hua K, Jin J, Zhao J, Song J, Song H, Li D, et al. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2 expression of concern in /10.3892/ijo.2025.5802. Int J Oncol. (2016) 48:1997–2006. doi: 10.3892/ijo.2016.3405 [DOI] [PubMed] [Google Scholar]
- 70. Lou J, Liu X, Xie Y, Wu M, Mao W, Ying X. MiR-301b-3p promotes breast cancer development through inhibiting the expression of transforming growth factor-beta receptor 2. PeerJ. (2024) 12:e18324. doi: 10.7717/peerj.18324 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71. Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. (2014) 16:435. doi: 10.1186/s13058-014-0435-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol. (2012) 189:4175–81. doi: 10.4049/jimmunol.1201516 [DOI] [PubMed] [Google Scholar]
- 73. Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W, et al. MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance, and applications in human triple-negative breast cancer. Cells. (2019) 8:1492. doi: 10.3390/cells8121492 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Dongre S, Soni N, Chaudhary M, Prakasan A, Sharma A, Bissa B. Enigma of AMP-activated protein kinase subunit expression in glioma Academia Oncology (2025). Available online at: https://www.academia.edu/2998-7741/2/3/10.20935/AcadOnco7881 (Accessed October 3, 2025).
- 75. Dongre S, Sharma A, Soni N, Bissa B. AMPK γ-subunit isoform switching governs temozolomide resistance and survival in glioblastoma. (2026). doi: 10.20944/preprints202605.1585.v1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Wang J-G, Jian W-J, Li Y, Zhang J. Nobiletin promotes the pyroptosis of breast cancer via regulation of miR-200b/JAZF1 axis. Kaohsiung J Med Sci. (2021) 37:572–82. doi: 10.1002/kjm2.12371 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Xu W, Song C, Wang X, Li Y, Bai X, Liang X, et al. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis. Aging (Albany NY). (2021) 13:228–40. doi: 10.18632/aging.103669 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Wang Y, Han Z, Fan Y, Zhang J, Chen K, Gao L, et al. MicroRNA-9 inhibits NLRP3 inflammasome activation in human atherosclerosis inflammation cell models through the JAK1/STAT signaling pathway. Cell Physiol Biochem. (2017) 41:1555–71. doi: 10.1159/000470822 [DOI] [PubMed] [Google Scholar]
- 79. Xie Q, Wei M, Zhang B, Kang X, Liu D, Zheng W, et al. MicroRNA-33 regulates the NLRP3 inflammasome signaling pathway in macrophages. Mol Med Rep. (2018) 17:3318–27. doi: 10.3892/mmr.2017.8224 [DOI] [PubMed] [Google Scholar]
- 80. Hamza S, Garanina EE, Shkair L, Alsaadi M, Khaiboullina SF, Tezcan G. Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer. Pharmaceuticals. (2024) 17:299. doi: 10.3390/ph17030299 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Hu Y, Wu D, Feng X, Shi Z. Research on the effect of interfering with miRNA-155 on triple-negative breast cancer cells. Genes Genom. (2022) 44:1117–24. doi: 10.1007/s13258-021-01106-y [DOI] [PubMed] [Google Scholar]
- 82. Loh H-Y, Norman BP, Lai K-S, Rahman NMANA, Alitheen NBM, Osman MA. The regulatory role of microRNAs in breast cancer. Int J Mol Sci. (2019) 20:4940. doi: 10.3390/ijms20194940 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Ni J, Chen Y, Fei B, Zhu Y, Du Y, Liu L, et al. MicroRNA-301a promotes cell proliferation and resistance to apoptosis through PTEN/PI3K/Akt signaling pathway in human ovarian cancer. Gynecol Obstet Invest. (2021) 86:108–16. doi: 10.1159/000513070 [DOI] [PubMed] [Google Scholar]
- 84. Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, et al. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. Gene. (2014) 535:191–7. doi: 10.1016/j.gene.2013.11.035 [DOI] [PubMed] [Google Scholar]
- 85. Liu H, Wang G. MicroRNA-301a-3p promotes triple-negative breast cancer progression through downregulating MEOX2. Exp Ther Med. (2021) 22:945. doi: 10.3892/etm.2021.10377 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest. (2013) 123(2):566–579. doi: 10.1172/JCI65871 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Ma J, Gan L, Chen H, Chen L, Hu Y, Luan C, et al. Upregulated miR-374a-5p drives psoriasis pathogenesis through WIF1 downregulation and Wnt5a/NF-κB activation. Cell Signalling. (2024) 119:111171. doi: 10.1016/j.cellsig.2024.111171 [DOI] [PubMed] [Google Scholar]
- 88. Shukla A, Sharma A, Gupta S, Mishra A, Singh A. Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts. Med Oncol. (2025) 42:169. doi: 10.1007/s12032-025-02726-0 [DOI] [PubMed] [Google Scholar]
- 89. Shukla A, Sharma A, Gupta S, Raut S, Mishra A, Hemalatha S, et al. Structure-guided discovery of a novel BTK inhibitor inducing apoptosis and G1 phase arrest in tumor cells. Mol Divers. (2025) 30(3):3857–3880. doi: 10.1007/s11030-025-11334-z [DOI] [PubMed] [Google Scholar]
- 90. Molla MD, Akalu Y, Geto Z, Dagnew B, Ayelign B, Shibabaw T. Role of caspase-1 in the pathogenesis of inflammatory-associated chronic noncommunicable diseases. J Inflammation Res. (2020) 13:749–64. doi: 10.2147/JIR.S277457 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Jridi I, Canté-Barrett K, Pike-Overzet K, Staal FJT. Inflammation and Wnt signaling: target for immunomodulatory therapy? Front Cell Dev Biol. (2021) 8. doi: 10.3389/fcell.2020.615131 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Wu L, Pu L, Zhuang Z. miR-155-5p/FOXO3a promotes pulmonary fibrosis in rats by mediating NLRP3 inflammasome activation. Immunopharmacol Immunotoxicol. (2023) 45:257–67. doi: 10.1080/08923973.2022.2115923 [DOI] [PubMed] [Google Scholar]
- 93. Kim NH, Kim HS, Kim N-G, Lee I, Choi H-S, Li X-Y, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signaling. (2011) 4:ra71–1. doi: 10.1126/scisignal.2001744 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94. Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal SA, et al. MiR-223-3p in cancer development and cancer drug resistance: same coin, different faces. Int J Mol Sci. (2024) 25:8191. doi: 10.3390/ijms25158191 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95. Li Y, Fu Z, Deng C, Qian J, Wang Z, Lu Y, et al. miR-301a-5p regulated IKKβ/NF-κB axis and macrophage polarization to accelerate skin wound healing. Int J Biol Macromol. (2025) 311:143995. doi: 10.1016/j.ijbiomac.2025.143995 [DOI] [PubMed] [Google Scholar]
- 96. Gupta S, Sharma A, Shukla A, Mishra A, Singh A. From development to clinical success: the journey of established and next-generation BTK inhibitors. Invest New Drugs. (2025) 43(2):377–393. doi: 10.1007/s10637-025-01513-y [DOI] [PubMed] [Google Scholar]
- 97. Sharma A, Raut SS, Shukla A, Gupta S, Singh A, Mishra A. Phytochemical triad in lung cancer: synergistic mechanisms and clinical translation of genistein, piperine, and resveratrol. Mol Nutr Food Res. (2026) 70:e70348. doi: 10.1002/mnfr.70348 [DOI] [PubMed] [Google Scholar]
- 98. Singh S, Sharma A, Pandey T, Gupta S, Shukla A, Singh SK, et al. Silibinin: a natural flavonoid with multifaceted anticancer potential and therapeutic challenges. Med Chem Res. (2025) 34:2115–36. doi: 10.1007/s00044-025-03466-630311153 [DOI] [Google Scholar]
- 99. Liang J, Pan Y, Yang J, Zeng D, Li J. WNT signaling in cancer: molecular mechanisms and potential therapies. Mol BioMed. (2025) 6:83. doi: 10.1186/s43556-025-00327-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Huang L, Luo R, Li J, Wang D, Zhang Y, Liu L, et al. β-catenin promotes NLRP3 inflammasome activation via increasing the association between NLRP3 and ASC. Mol Immunol. (2020) 121:186–94. doi: 10.1016/j.molimm.2020.02.017 [DOI] [PubMed] [Google Scholar]
- 101. Saadh MJ, Jasim NY, Ahmed MH, Ballal S, Kumar A, Atteri S, et al. Critical roles of miR-21 in promotions angiogenesis: friend or foe? Clin Exp Med. (2025) 25:66. doi: 10.1007/s10238-025-01600-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102. Zheng J-Z, Huang Y-N, Yao L, Liu Y-R, Liu S, Hu X, et al. Elevated miR-301a expression indicates a poor prognosis for breast cancer patients. Sci Rep. (2018) 8:2225. doi: 10.1038/s41598-018-20680-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. Piña-Sánchez P, Valdez-Salazar H-A, Ruiz-Tachiquín M-E. Circulating microRNAs and their role in the immune response in triple-negative breast cancer (Review). Oncol Lett. (2020) 20:1. doi: 10.3892/ol.2020.12087 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104. Rosado-Sanz M, Martínez-Alarcón N, Abellán-Soriano A, Golfe R, Trinidad EM, Font de Mora J. Cytokine networks in triple-negative breast cancer: mechanisms, therapeutic targets, and emerging strategies. Biomedicines. (2025) 13:1945. doi: 10.3390/biomedicines13081945 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105. Preethi KA, Selvakumar SC, Ross K, Jayaraman S, Tusubira D, Sekar D. Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer. Mol Cancer. (2022) 21:54. doi: 10.1186/s12943-022-01525-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
